Allarity Therapeutics, Inc. - Common stock (ALLR)
0.8831
-0.0259 (-2.85%)
NASDAQ · Last Trade: Jun 11th, 4:46 PM EDT
Detailed Quote
Previous Close | 0.9090 |
---|---|
Open | 0.9045 |
Bid | 0.8876 |
Ask | 0.8880 |
Day's Range | 0.8622 - 0.9045 |
52 Week Range | 0.6138 - 16.50 |
Volume | 288,828 |
Market Cap | 175.51M |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 546,157 |
Chart
About Allarity Therapeutics, Inc. - Common stock (ALLR)
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies that target specific molecular drivers of tumors. The company utilizes its proprietary drug development platform to identify and enhance the effectiveness of treatments tailored for individual patient profiles, particularly in cases of advanced or difficult-to-treat cancers. By leveraging advanced technologies, Allarity aims to improve patient outcomes through personalized medicine approaches that align therapies with the unique characteristics of a patient's tumor, ultimately striving to bring more effective options to the oncology landscape. Read More
News & Press Releases
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that Jesper Høiland has been appointed to join the Company’s Board of Directors. He will be replacing Joseph Vazzano, who will resign from the Board effective on June 30, 2025, following his valuable contributions to Allarity’s development over the past two years.
By Allarity Therapeutics, Inc. · Via GlobeNewswire · June 11, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · June 4, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · June 2, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · May 12, 2025
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months- Initiated utilization of share repurchase program- Cash and restricted cash balance of approximately $27 million at end of Q1 2025, reinforcing financial stability
By Allarity Therapeutics, Inc. · Via GlobeNewswire · May 9, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · April 25, 2025
U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s “Liberation Day”, the term he’s used for April 2nd, the day of incoming reciprocal tariffs, preceded a drop in stock prices.
Via Benzinga · April 1, 2025
Via Benzinga · April 1, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 31, 2025
Via Benzinga · March 24, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 24, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 17, 2025
By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 13, 2025

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among Stocktwits users for the week ended March 7, 2025.
Via Stocktwits · March 10, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 6, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · March 3, 2025

Boston (February 26, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced that the securities class action lawsuit in the United States District Court for the Southern District of New York referenced in the Company’s Form 10-Q filing on November 11, 2024, has been dismissed in whole against all defendants.
By Allarity Therapeutics, Inc. · Via GlobeNewswire · February 26, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · February 24, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · February 6, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · January 30, 2025

By Allarity Therapeutics, Inc. · Via GlobeNewswire · November 18, 2024

By Allarity Therapeutics, Inc. · Via GlobeNewswire · November 14, 2024

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · November 12, 2024

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) and reminds investors of the November 12, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · November 12, 2024

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · November 9, 2024